Correction to: Ruxolitinib therapy formyelofibrosis in Austria
Maria‐Theresa Krauth(Medical University of Vienna), Heinz Gisslinger(Medical University of Vienna), Andreas Petzer(Ordensklinikum Linz Barmherzige Schwestern), Peter Krippl, Holger Rumpold(Innsbruck Medical University), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Albert Wölfler(Medical University of Graz), Stefan Wöhrer(Fachhochschule Wiener Neustadt), Klaus Geißler(University of Vienna), Thomas Melchardt(Paracelsus Medical University), Felix Keil(Hanusch Hospital), Sonja Burgstaller(Klinikum Wels-Grieskirchen), Günther Gastl(Innsbruck Medical University), Thamer Sliwa(Hanusch Hospital)
Cited by 0
Related Papers
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
Erythropoietin Treatment of Anemia Associated with Multiple Myeloma
|New England Journal of Medicine|1990|450